Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: Possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum

Japanese Journal of Clinical Oncology

Volumn 31, Issue 5, 2001, Pages 179-184

  Hanada, Kazuhiko ^a   Nishijima, Kazuyuki ^a   Ogata, Hiroyasu ^a   Atagi, Shinji ^b   Kawahara, Masaaki ^b  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

Cisplatin; Filtered platinum; Population pharmacokinetic analysis; Total platinum

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; DRUG METABOLITE; ETOPOSIDE; GAMMA GLUTAMYLTRANSFERASE; IRINOTECAN; LACTATE DEHYDROGENASE; MITOMYCIN C; N ACETYL BETA GLUCOSAMINIDASE; NITROGEN; PLATINUM; UREA; VINCA ALKALOID;

ADULT; AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BLOOD SAMPLING; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INFUSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PHARMACODYNAMICS;

EID: 0034937675     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hye040     Document Type: Article

References (15)

1. Clinical and pharmacological studies with cis-diamminedichloroplatinum(II)
2. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and anti-tumour activity of cisplatin
3. Decomposition kinetics of cisplatin in human biological fluids
4. Characterization of the reactions of platinum anti-tumor agents with biologic and nonbiologic sulfur-containing nucleophiles
5. Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum(II) (DDP) in the tumored rat
6. High-performance liquid chromatographic analysis of unchanged cis-diamminedichloroplatinum (cisplatin) in plasma and urine with post-column derivatization
7. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: Relationship between renal handling and nephrotoxicity of cisplatin
8. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin in rats and on the distribution of platinum species in rat kidney: Protective mechanism against cisplatin nephrotoxicity
9. Evaluation of methods for estimating population pharmacokinetics parameters. III. Monoexponential model: Routine clinical pharmacokinetic data
10. The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods
11. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: Analysis with the NONMEM program
12. Quantitative determination of unchanged cisplatin in rat kidney and liver by high-performance liquid chromatography
13. Cisplatin metabolites: A method for their separation and for measurement of their renal clearance in vivo
14. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer